<i>SCN1A, ABCC2</i> and <i>UGT2B7</i> Gene Polymorphisms in Association with Individualized Oxcarbazepine Therapy

Abstract

SCN1A, UGT2B7 and ABCC2 genetic polymorphisms are associated with OXC maintenance doses and may be useful for the personalization of OXC therapy in epileptic patients. Further studies are needed. Original submitted 6 June 2014; Revision submitted 5 September 2014.